Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium
Details of the poster presentation are as follows:
Title: Tumor Infiltration and Cytokine Biomarkers of Prostate Stem Cell Antigen (PSCA)-Directed GoCAR-T® Cells in Patients with Advanced Pancreatic Tumors
Poster Board: M1, Abstract 734
Presenter:
Time/Location:
About
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and allogeneic cell therapies. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com.
Source:
Investors:
Managing Director
Westwicke IR
858-356-5932
Robert.uhl@westwicke.com
Media:
Senior Vice President
Westwicke PR
203-682-8210
kate.coyle@icrinc.com
Source: Bellicum Pharmaceuticals, Inc.